Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 16/20 | 0.88 |
| ▸ | DRD2 | P14416 | 9/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.88 |
| ▸ | RECQL | P46063 | 4/20 | 0.88 |
| ▸ | BLM | P54132 | 3/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.88 |
| ▸ | THPO | P40225 | 3/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.88 |
| ▸ | DRD3 | P35462 | 2/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.88 |
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | TSHR | P16473 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.88 |
| ▸ | KDM1A | O60341 | 1/20 | 0.88 |
| ▸ | HTR1A | P08908 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoldopam SCHEMBL41214 | 0.94 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL13287212 | 0.94 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157427 | 0.94 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1815791 | 0.94 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL34250 | 0.94 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL11215595 | 0.93 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1319766 | 0.93 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157381 | 0.93 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL16241872 | 0.93 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL29424282 | 0.93 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316731-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | WEINSTOCK JOSEPH | 2010-12-16 | — | — | US | claimed |
| EP-2170343-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Weinstock, Joseph (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2008150954-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | WEINSTOCK JOSEPH (US) | 2008-12-11 | — | — | WO | claimed |
| US-9072749-B2 | Treatment of age-related macular degeneration | WEINSTOCK JOSEPH (US) | 2015-07-07 | — | — | US | disclosed |
| US-20100316731-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | WEINSTOCK JOSEPH | 2010-12-16 | — | — | US | disclosed |
| EP-2170343-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Weinstock, Joseph (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008150954-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | WEINSTOCK JOSEPH (US) | 2008-12-11 | — | — | WO | disclosed |
| EP-0380355-B1 | Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-Hydroxyphenyl)-2,3,4,5-tetra-hydro-1H-3-benzazepine as prodrugs | SMITHKLINE BEECHAM CORP (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0380355-A2 | Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-Hydroxyphenyl)-2,3,4,5-tetra-hydro-1H-3-benzazepine as prodrugs | SMITHKLINE BEECHAM CORPORATION (US) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316731-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | AGER, ALDH1A2, PDE6D | DRD1 4086/4885DRD2 3967/4885KDM4E 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.